Phuturdex › Drugs › Elamipretide
Drugs in development · updated 10 November 2026
Elamipretide: clinical trials and development status
Other names and codes: Forzinity
As of 10 November 2026 Elamipretide is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 2 diseases. The most advanced phase is III.
Summary updated every week · data as of 10 November 2026. In Phuturdex you can follow Elamipretide and get an email at every change or safety alert.
Sign in free →Approved uses in the United States (FDA)
FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. […]
Official documents
- Forzinity: FDA label (DailyMed) · FDA version of 10 December 2025
Use, doses, side effects and interactions: only these official documents are authoritative.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Macular degeneration | III | 1 | NCT06373731 |
| Barth syndrome | I | 1 | NCT07927972 |
Sites in Europe
20 sites of the active trials in 6 European countries, 0 recruiting.
- Italy5
- Spain4
- United Kingdom4
- Germany3
- Hungary3
- Czechia1
Sites declared by the sponsors on ClinicalTrials.gov; region worked out by Phuturdex from the geographic point. The list of sites with city and recruitment status is in the app. See the sites →
Everything on Elamipretide
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 10 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.